β-HCG与肝细胞癌的相关性研究  

Diagnostic value of serum β-HCG in hepatocellular carcinoma

作　　者：邢正云[1] 冯国安[2] 王光红[2] 

机构地区：[1]江苏省大丰市中医院,江苏大丰224100 [2]山东大学临床医学院济南市中心医院,山东济南250013

出　　处：《实用肿瘤杂志》2005年第4期308-310,共3页Journal of Practical Oncology

摘　　要：目的评估人绒毛膜促性腺激素(-βHCG)检测在肝细胞癌(HCC)诊断和预后中的价值。方法用微粒子酶免发光技术(MEIA)测定83例HCC患者,25例肝硬化患者和62名正常人血清的5种HCC血清标志物,包括-βHCG、甲胎蛋白(AFP)、糖链抗原19-9(CA19-9)、糖链抗原125(CA125)、癌胚抗原(CEA)。结果通过5种血清学指标检测,HCC患者5种血清学指标与肝硬化组和正常人组比较差异均有显著性(P<0.01),-βHCG和AFP在Ⅰ期HCC和Ⅱ、Ⅲ期HCC中表达差异无显著性。部分AFP阴性患者-βHCG可阳性。结论-βHCG检测可提高HCC早期诊断率,同时,也可能为HCC生物治疗提供一个新的靶点。Objective To evaluate the diagnostic value of β-HCG in hepatocellular carcinoma （HCC）. Methods Serum levels of 5 tumor markers （β-HCG, AFP, CA19-9, CA125, CEA） were measured with microparticle enzyme immunoassay （MEIA） in 83 patients with HCC,25 patients with hepatocirrhosis and 62 healthy controls. Results The serum levels of β-HCG, AFP,CA19-9 ,CA125 and CEA in HCC patients were significantly higher than those in the control and hepatocirrhosis groups （P〈0. 01）. However,there were no statistical differences between β-HCG and AFP levels in early HCC and advanced HCC cases. Conclusion The detection of serum β-HCG levels may increase the diagnostic rate of early HCC cases.

关 键 词：绒毛膜促性腺激素 Β亚基 人/血液 肿瘤标记 生物学/分析 癌 肝细胞/诊断 免疫酶技术 

分 类 号：R735.7[医药卫生—肿瘤]